Type 3 Phosphodiesterase Inhibitors May Be Protective Against Cerebrovascular Events in Patients with Claudication

Journal of Stroke and Cerebrovascular Diseases

Volumn 17, Issue 3, 2008, Pages 129-133

  Stone, William M ^a   Demaerschalk, Bart M ^a   Fowl, Richard J ^a   Money, Samuel R ^a  

^a MAYO CLINIC   (United States)

Author keywords

cerebrovascular accident; claudication; peripheral vascular disease; Prevention

Indexed keywords

CILOSTAZOL; PHOSPHODIESTERASE III INHIBITOR; PLACEBO;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN PROTECTION; CEREBRAL REVASCULARIZATION; CLAUDICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POST HOC ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SINGLE BLIND PROCEDURE; STATISTICAL ANALYSIS; STROKE; STROKE PATIENT; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

AGED; CARDIOVASCULAR AGENTS; CEREBROVASCULAR DISORDERS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PHOSPHODIESTERASE INHIBITORS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME;

EID: 43049183212     PISSN: 10523057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2007.12.005     Document Type: Article

References (19)

1. Newman A.B., Siscovick D.S., Manolio T.A., et al. Atherosclerosis: Ankle-arm index as a marker of atherosclerosis in the cardiovascular health study. Circulation 88 (1993) 837-845
2. CAPRIE Steering Committee. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 348 (1996) 1329-1339
3. Hayden M., Pignone M., Phillips C., et al. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the US preventive services task force. Ann Intern Med 136 (2000) 161-172
4. Halkes P., van Gijn J., Kappelle L., et al. Aspirin plus dipyridamole vs. aspirin alone after cerebral ischemia of arterial origin (ESPRIT): Randomized controlled trial. Lancet 367 (2006) 1665-1673
5. Bhatt D., Fox K., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
6. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324 (2002) 71-86
7. Kambayashi J., Liu Y., Sun B., et al. Cilostazol as a unique antithrombotic agent. Curr Pharm Des 9 (2003) 2289-2302
8. Packer M. Cardiovascular and Renal Drugs Advisory Committee, 85th Meeting, July 9, 1998. Bethesda, MD: Food and Drug Administration, U.S. Department of Health and Human Services.
9. Gotoh F., Tohgi H., Hirai S., et al. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis 9 (2000) 147-157
10. Hiatt W.M., Money S.R., and Brass E.P. Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: a study in long-term effects). J Vasc Surg 47 (2008) 330-336
11. Goldstein L.B., Adams R., Alberts M.J., et al. Guidelines for prevention of stroke in patients with ischemic strokes or transient ischemic attacks: A statement for healthcare professionals from the American Heart Association/American Stroke Association council on stroke; co-sponsored by the council on cardiovascular radiology and intervention, the American Academy of Neurology affirms the value of this guideline. Stroke 37 (2006) 577-617
12. Storey R.F., Sanderson H.M., White A.E., et al. The central role of the P(2T) receptor in amplification of human platelet activation, aggregation, secretion and procoagulant activity. Br J Haematol 110 (2000) 925-934
13. Peter K., Schwarz M., Ylanne J., et al. Induction of fibrinogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/IIIa (alphaIIbbeta3) inhibitors. Blood 92 (1998) 3240-3249
14. Aktas B., Utz A., Hoenig-Liedl P., et al. Dipyridamole enhances NO/cGMP-mediated vasodilator-stimulated phosphoprotein phosphorylation and signaling in human platelets: In vitro and in vivo/ex vivo studies. Stroke 34 (2003) 764-769
15. Kimura Y., Tani T., Kanbe T., et al. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 35 (1985) 1144-1149
16. Horiuchi M., Sugihara H., Koboyashi H., et al. Effect of cilostazol on carotid blood and cutaneous microcirculation flows. Diagn Treat 84 (1996) 523-530
17. Elam M.B., Heckman J., Crouse J.R., et al. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol 18 (1998) 1942-1947
18. Kwon S.U., Cho Y.J., Koo J.S., et al. Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 36 (2005) 782-786
19. Take S., Matsutani M., Ueda H., et al. Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 79 (1997) 1097-1099